# Addus HomeCare Corporation (ADUS)

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-27  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/ADUS/primer

## Business Model

---
source: coverage-next-full
ticker: ADUS
step: 01
title: Business Overview & Value Chain
generated: 2026-05-27
---

### Step 01 — Business Overview & Value Chain: Addus HomeCare Corporation (ADUS)

#### 1. Business Description

Addus HomeCare Corporation is a Frisco, Texas-based provider of home- and community-based services, operating three distinct segments that collectively serve patients across 21+ states. [S1] Founded in 1979 and public since 2009, the company has evolved from a primarily Illinois-based personal care agency into one of the largest independent multi-state home care platforms in the United States.

**Core Mission:** Enable medically complex and functionally limited individuals — predominantly elderly Medicaid/Medicare "dual eligibles" — to receive care in their homes rather than in higher-cost institutional settings (nursing homes, hospitals).

**FY2025 Revenue by Segment:**
| Segment | Revenue | % of Total | Key Payor |
|---------|---------|-----------|-----------|
| Personal Care | ~$1,100M est. | ~77% | Medicaid / HCBS / MCOs |
| Hospice | ~$213M est. | ~15% | Medicare / Medicaid |
| Home Health | ~$110M est. | ~8% | Medicare / MCOs |
| **Total** | **$1,423M** | **100%** | |

[S1: 10-K FY2025, Q1 2026 8-K]

#### 2. Three-Segment Business Model

##### Segment 1: Personal Care (Core Business, ~77% of Revenue)
- **Service:** Non-medical assistance with activities of daily living (ADLs): bathing, dressing, grooming, mobility assistance, light housekeeping, meal preparation, companionship
- **Consumers:** Predominantly elderly, disabled, or functionally limited individuals with Medicaid eligibility; heavily "dual eligible" (Medicare + Medicaid)
- **Employees:** Personal Care Aides (PCAs), Home Health Aides (HHAs) — paraprofessional, typically hourly, no clinical license required
- **Payor:** State Medicaid agencies directly, and increasingly Medicaid Managed Care Organizations (MCOs) that have assumed HCBS risk from states
- **Revenue model:** Hours of service delivered × contracted hourly rate (set by state or MCO contract)
- **Key geographies (FY2025):** Illinois (historic core, ~30-35% est.), Texas (expanded via Gentiva acquisition), Indiana, Ohio, Missouri, and 15+ other states

##### Segment 2: Hospice (~15% of Revenue)
- **Service:** End-of-life care for terminally ill patients (typically prognosis of ≤6 months); includes pain management, spiritual support, family counseling
- **Employees:** Registered nurses, social workers, chaplains, hospice aides — multidisciplinary team model
- **Payor:** Medicare Hospice Benefit (primary), Medicaid
- **Revenue model:** Per-diem rate × days enrolled (4 levels of care: routine home care, continuous home care, general inpatient, respite)
- **Regulatory note:** Medicare sets national per-diem rates; hospice election reduces other Medicare spending creating value for the payer

##### Segment 3: Home Health (~8% of Revenue)
- **Service:** Skilled nursing, physical therapy, occupational therapy, speech therapy — post-acute or chronic disease management
- **Employees:** Registered nurses, licensed physical/occupational/speech therapists
- **Payor:** Medicare, Medicare Advantage (MCOs), Medicaid
- **Revenue model:** Per-episode (PDGM under Medicare) or per-visit
- **Dynamics:** Subject to Medicare rate cuts; ADUS home health has been the softest segment in recent quarters [S2]

#### 3. Value Chain Layer Map

```
UPSTREAM (Referral & Contract)
├── State Medicaid Agencies → set HCBS rates, award contracts
├── Medicaid MCOs → negotiate per-member-per-month or hourly rates
├── Medicare → set hospice per-diems (national) + home health PDGM rates
├── Hospitals / SNFs / ACOs → discharge planning, referral source for home health + hospice
└── Physicians / Palliative Care teams → hospice order, home health order

MIDSTREAM (ADUS Operations)
├── Central Services: HR, recruitment, training, compliance, EVV technology
├── Branch Operations: ~250+ care centers across 21+ states
├── Caregiver Workforce: ~50,000+ personal care aides + clinical staff
├── Care Coordination: matching patients to caregivers, scheduling, quality monitoring
└── Billing & Collections: claims submission to state agencies/MCOs/Medicare

DOWNSTREAM (Consumer)
└── Patient/Consumer: elderly, dual-eligible, disabled individual at home
    ├── Outcome: avoid nursing home placement, reduce hospitalizations
    └── Value: ~60-80% cost reduction vs. institutional care
```

#### 4. Revenue Architecture (Unit Economics)

**Personal Care Unit Economics:**
- Revenue per hour: $20-25 (set by state Medicaid / MCO contracts; varies significantly by state)
- Caregiver wage: $15-19/hr (varies by state; minimum wage floors increasingly binding)
- Direct cost ratio: ~67% of revenue (caregiver wages + benefits + workers' comp)
- Gross margin: ~33% (net of caregiver costs)
- SG&A: ~23% of revenue (branch overhead, compliance, corporate)
- EBITDA margin: ~10-11%

**Hospice Unit Economics:**
- Average daily census: Growing; hospice per-diem from Medicare (FY2025 routine rate ~$228/day)
- ADUS hospice: Higher-margin segment than personal care (Medicare rates historically more stable)

**Home Health Unit Economics:**
- PDGM: 60-day episode payment varying by diagnosis + functional status; Medicare rate pressure ongoing

#### 5. Geographic Footprint
- **States served:** 21+ states across Midwest, Mid-Atlantic, South, and Southwest
- **Key states:** Illinois (personal care legacy), Texas (Gentiva expansion), Indiana, Ohio, Missouri, North Carolina, Georgia
- **New York:** Divested personal care operations in FY2025 due to CDPAP regulatory restructuring [S1]
- **Branch network:** ~250+ local care centers (branches)

#### 6. Customer Profile
- **Age:** Predominantly 65+; significant 75-85+ cohort
- **Functional status:** Require assistance with ≥2 ADLs; many have multiple chronic conditions
- **Payor status:** "Dual eligible" (Medicare + Medicaid) is the core; also Medicaid-only and Medicare-only
- **Key characteristic:** Sticky — consumers often stay with the same caregiver for years; high switching cost for patient

#### 7. Competitive Positioning Summary
- **Scale advantage:** Top-5 independent personal care provider nationally post-Gentiva
- **Technology:** EVV compliance, scheduling algorithms — operational efficiency vs. smaller independents
- **Managed care relationships:** Long-term MCO contracts create revenue visibility
- **Geographic density:** Key in Illinois/Midwest; building density in South/Southwest via acquisitions

#### Source Index
- [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
- [S2] Q1 2026 Earnings (8-K, May 2026) — Stocktitan.net summary
- [S3] StockAnalysis.com ADUS Overview — stockanalysis.com/stocks/adus/

## Financial Snapshot

---
source: coverage-next-full
ticker: ADUS
step: 04
title: Financial Quality & Adversarial Sweep
generated: 2026-05-27
---

### Step 04 — Financial Quality & Adversarial Research Sweep: Addus HomeCare Corporation (ADUS)

#### 1. Financial Statement Quality Assessment

##### Revenue Recognition
- **Method:** Services delivered basis — revenue recognized when personal care hours are delivered, hospice days are served, or home health visits are completed [S1]
- **Quality:** HIGH. No complex arrangements, no percentage-of-completion, no deferred revenue structures. Service delivery is the single trigger.
- **EVV verification:** Electronic Visit Verification provides a real-time audit trail of care delivery, reducing billing disputes and fraud risk
- **Adjustments needed:** NONE significant. Revenue as reported is reliable.

##### Cost of Revenue
- Predominantly caregiver wages + benefits + workers' compensation insurance
- Payroll timing: Weekly/bi-weekly; no significant timing distortions
- Workers' comp: Self-insured to varying degrees by state; actuarial reserves reflect expected claims
- **Quality:** HIGH. Direct labor cost is straightforward to verify against payroll records.

##### Goodwill ($997M = 70% of total assets as of FY2025)
- Largest balance sheet item; reflects 20+ acquisitions over 10+ years
- Annual impairment testing required (ASC 350); no goodwill impairment charges recorded in FY2021-FY2025 [S1]
- **Risk:** If acquired businesses underperform (e.g., Gentiva integration fails), impairment charges could be material (~$100-300M non-cash write-down possible in adverse scenario)
- **Assessment:** Management has consistently delivered accretive acquisitions; goodwill level is elevated but supported by stable cash flows

##### Intangible Assets ($102M)
- Primarily customer relationships, non-compete agreements, and trade names acquired via M&A
- Amortized over useful lives (7-20 years typically for customer relationships)
- Annual amortization ~$15-17M; reduces GAAP earnings but not economic earnings
- **Adjusted EBITDA addback:** Amortization is legitimately added back to understand economic earnings

##### Deferred Revenue / Working Capital
- No significant deferred revenue
- Working capital: Accounts receivable ~$200-250M (Medicaid/Medicare — typically 45-90 day payment cycles)
- DSO (Days Sales Outstanding): ~60-75 days (typical for government payor); government is slower but reliable
- **Quality:** MEDIUM. Medicaid AR can be complex; some state-specific payment delays occur. No evidence of channel stuffing or premature revenue recognition.

##### Earnings Quality Score: **B+ (High Quality)**
- Core operations generate genuine cash flows: OCF/Net Income ratio ~1.15-1.2x (above 1.0 = good quality)
- SBC (~$18-20M/year) reduces cash compensation but is a real economic cost; GAAP earnings appropriately reflect this
- No significant one-time items manipulating reported results (integration costs disclosed separately as "non-cash" but cash is still deployed)

#### 2. Adjusted Earnings vs. GAAP Reconciliation (FY2025)

| Metric | GAAP | Adjustment | Adjusted |
|--------|------|-----------|---------|
| Net Income | $96M | — | $96M |
| Add: Amortization | — | +$16M | — |
| Add: SBC | — | +$18M | — |
| Add: D&A (ex-amortization) | — | +$5M | — |
| Less: Tax on addbacks | — | (~$9M) | — |
| **Adjusted EBITDA** | — | — | **~$155M** |
| **Adjusted EPS (est.)** | **$5.22** | +$1.30 adj. | **~$6.40-6.50** |

*Note: Management uses "Adjusted EPS" excluding amortization of acquired intangibles; Q1 2026 reported $1.62 adjusted EPS vs. $1.36 GAAP [S2]*

#### 3. Adversarial Research Sweep

**Methodology:** Searched for short-seller reports, regulatory investigations, class action lawsuits, whistleblower filings, and bearish institutional research. Transcript analysis not performed (coverage-next-full path).

##### Finding 1: No Active Short-Seller Reports
- No published short-seller thesis found (Hindenburg, Muddy Waters, Citron, etc.)
- Short interest: Modest; MarketBeat shows routine short interest without spike indicators [S3]
- Assessment: **Clean** — no organized short-side campaign targeting ADUS

##### Finding 2: New York CDPAP Divestiture (Regulatory Adverse Event)
- **What happened:** New York's Consumer Directed Personal Assistance Program (CDPAP) underwent restructuring in 2024-2025; state created a new fiscal intermediary (FI) model; ADUS determined its NY operations were no longer financially viable
- **Impact:** Divested NY personal care operations; revenue loss not disclosed but material enough to trigger divestiture; ADUS cited "changes and uncertainty in New York regarding the CDPAP" [S1]
- **Assessment:** RESOLVED — NY operations exited; no ongoing NY regulatory risk. Demonstrates that state regulatory changes CAN force business model exits. Bears cite this as evidence that reimbursement risk is real and not theoretical.

##### Finding 3: Medicaid Billing Compliance Risk
- Home health and hospice companies are perennial OIG targets for false claims and billing fraud
- ADUS 10-K discloses routine legal proceedings; no material OIG investigation or settlement found [S1]
- EVV mandate compliance reduces personal care billing abuse risk
- **Assessment:** LOW RISK — No material compliance issue identified; EVV reduces fraud exposure vs. pre-EVV era

##### Finding 4: OBBBA Medicaid Eligibility Restrictions
- "One Big Beautiful Bill Act" (Trump-era federal legislation) includes provisions limiting Medicaid eligibility (immigration status restrictions, work requirements)
- ADUS is exposed: If Medicaid rolls shrink, personal care census shrinks proportionally
- **Assessment:** ACTIVE RISK — Not a fraud concern but a legitimate business risk. Effect size uncertain; Congressional outcomes subject to change.

##### Finding 5: Insider Selling Pattern
- Multiple insiders sold shares over 2024-2025 via 10b5-1 plans [S4]
- No open-market buying documented in the same period
- **Assessment:** MILD YELLOW FLAG — Selling is routine (tax-driven) but absence of open-market buying reduces conviction signal from insiders. CEO's 1.6% stake ($16M at current price) is material but not dominant.

##### Finding 6: Goodwill Concentration / Acquisition Risk
- $997M goodwill on $1.43B revenue and $1.08B equity — balance sheet is goodwill-heavy
- Gentiva acquisition ($340M, closed 2024) is the largest single acquisition; integration still in progress [S1]
- **Assessment:** ONGOING RISK — Not a quality/fraud issue, but an execution risk. If Gentiva underperforms, non-cash impairment charges possible.

##### Finding 7: Labor Wage Pressure
- Caregiver wages are the dominant cost (67% of revenue); minimum wage increases in IL, TX, and other states create structural cost pressure
- **Assessment:** INDUSTRY-WIDE RISK — Not ADUS-specific; peers face identical dynamic. ADUS's scale and EVV efficiency somewhat mitigate vs. smaller players.

#### 4. Financial Statement Flags Summary

| Issue | Severity | Status |
|-------|---------|--------|
| Revenue recognition | Low | Clean; service delivery basis |
| Goodwill impairment risk | Medium | Active; Gentiva integration key |
| NY CDPAP exit | Medium | Resolved; demonstrates state risk |
| Medicaid billing compliance | Low | No active investigation |
| Insider selling | Low | Routine 10b5-1; not conviction-driven |
| OBBBA Medicaid cuts | Medium-High | Active; legislative uncertainty |
| Short-seller activity | None | No organized short campaign |

**Overall Financial Quality Rating: B+ / Low Concern**
Core business generates real cash flows; accounting is straightforward; principal risks are regulatory/political, not accounting-based.

#### 5. Quality Adjustments for Modeling
1. Use **Adjusted EBITDA** (~$155M FY2025) for valuation; add back amortization of acquired intangibles (~$16M)
2. Use **Adjusted EPS** for earnings power comparisons; adds back ~$0.90/share intangible amortization
3. Treat goodwill as a permanent asset for DCF purposes (no amortization under GAAP); test acquisition economics separately
4. FCF is the cleanest profitability measure: $104M FY2025 / $111M OCF after $8M CapEx

#### Source Index
- [S1] 10-K FY2025 (filed 2026-02-24) — SEC EDGAR
- [S2] Q1 2026 Earnings (8-K press release, May 2026) — via Stocktitan.net
- [S3] MarketBeat ADUS short interest — marketbeat.com/stocks/NASDAQ/ADUS/short-interest/
- [S4] SimplyWallSt — insider selling flag

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/adus
- Full research API: GET /api/v1/research/ADUS/memo
- Coverage universe: /stocks